biOasis Technologies Inc Share Price Toronto S.E.
Equities
BTI
CA09064N1033
Biotechnology & Medical Research
Sales 2021 | 4.08M 2.99M 233M | Sales 2022 | 37.72K 27.64K 2.16M | Capitalization | 19.32M 14.16M 1.11B |
---|---|---|---|---|---|
Net income 2021 | - 0 0 | Net income 2022 | -2M -1.47M -114M | EV / Sales 2021 | 5.7 x |
Net cash position 2021 | 2.62M 1.92M 150M | Net Debt 2022 | 171K 125K 9.79M | EV / Sales 2022 | 517 x |
P/E ratio 2021 |
35.1
x | P/E ratio 2022 |
-6.46
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.95% |
Managers | Title | Age | Since |
---|---|---|---|
Deborah Rathjen
CEO | Chief Executive Officer | - | 20/09/17 |
Dave Jenkins
DFI | Director of Finance/CFO | - | 30/06/21 |
Mei Mei Tian
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Hemeon
BRD | Director/Board Member | 59 | - |
David Wurzer
BRD | Director/Board Member | 65 | 26/07/18 |
Deborah Rathjen
CEO | Chief Executive Officer | - | 20/09/17 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |